Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae

Alex J. Holloway, Jieh Juen Yu, Bernard P. Arulanandam, Gregg N. Milligan, Tonyia D. Eaves-Pyles

Research output: Contribution to journalArticle

Abstract

We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae. We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 K. pneumoniae pneumonia. Results showed that rCST9/rCSTC treatment modulated endogenous serum biomarkers, cystatins 9 and C and amyloid A, associated with poor patient outcomes and provided prophylactic and long-term protection in a murine model of pneumonia.

Original languageEnglish (US)
Article numbere02519-18
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number5
DOIs
StatePublished - May 2019

Keywords

  • Adoptive B-cell transfer
  • Amyloid A
  • Cystatin 9
  • Cystatin C
  • Immunomodulation
  • Immunotherapy
  • Inflammation
  • Multidrug resistant
  • NDM-1 Klebsiella pneumoniae
  • Pneumonia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae'. Together they form a unique fingerprint.

  • Cite this